Microbial community structure and pharmaceuticals and personal care products removal in a membrane bioreactor seeded with aerobic granular sludge.

A process involving the use of membrane bioreactor seeded with aerobic granular sludge (GMBR) was applied to the treatment of sewage containing pharmaceuticals and personal care products (PPCPs). The removal effects of five kinds of medicines in the reactor were investigated, and the microbial communities were constructed by polymerase chain reaction and denaturing gradient gel electrophoresis. We also determined the effects of different sludge retention and hydraulic retention times (SRT and HRT, respectively) and influent organic loading on GMBR's efficiency in processing sewage containing PPCPs. The removal effects of the GMBR on five PPCPs varied. Using the GMBR, the removal rates of prednisolone, naproxen and norfloxacin were 98.56, 84.02 and 87.85%, respectively. The removal rates of sulfamethoxazole and ibuprofen were 77.83 and 63.32%, respectively. In the system, PPCP drugs had relatively less effect on microbial diversity. A certain succession was observed in the structural variation of microbial species in the GMBR. Microorganisms that can degrade PPCPs gradually accumulated, and antibiotic-resistant microorganisms, such as Firmicutes sp., Aeromonas sp. and Nitrospira sp., served a key function in the treatment of sewage containing antibiotics. Long SRT and HRT during the GMBR process can facilitate the removal of most PPCPs. The system efficiently removed PPCPs at high influent organic loading.

Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage

OBJECTIVE@#To investigate resistance and safety of HHPG-19K in treating non-small cell lung cancer patients.@*METHODS@#A total of 30 cases were selected and randomly divided into 5 groups: three HHPG-19K groups of different dosage (60 μg/kg/day, 100 μg/kg/day, 200 μg/kg/day), positive control group (Filgrastim, namely G-CSF5 μg/kg/day) and negative control group. Safety indexes of 5 groups were observed and compared.@*RESULTS@#All patients had adverse event (100%) in three HHPG-19K groups, and increased ALP, ALT and AST were main events. The degree was mild to moderate. There was no significant difference in the incidence of adverse event between dosage groups and positive control group no difference. But the incidence of negative control group was 13%, which was significantly lower than dosage groups and positive control group.@*CONCLUSIONS@#non-small cell lung cancer patients have satisfactory tolerance to HHPG-19K, and have no resistance. Besides, dosage at 100 μ g/kg is the most safe.